Bionano Genomics Inc (BNGO) — Cash Flow-to-Debt Ratio
Bionano Genomics Inc (BNGO) has a Cash Flow-to-Debt Ratio of -0.14x as of December 2025, meaning its operating cash flow of $-4.17 Million could theoretically repay 0% of its total liabilities ($29.16 Million) in one year. Explore Bionano Genomics Inc operating cash flow efficiency to assess how effectively this company generates cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Bionano Genomics Inc Cash Flow-to-Debt Ratio (2016–2025)
Historical debt coverage capacity for Bionano Genomics Inc across 10 annual periods. Also explore BNGO asset base for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Bionano Genomics Inc (2016–2025)
Year-by-year debt coverage analysis for Bionano Genomics Inc. For market capitalisation and broader financial context, see BNGO market cap overview.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.56x | $-16.34 Million | $29.16 Million | ▲ +66.4% |
| 2024 | -1.67x | $-68.92 Million | $41.30 Million | ▼ -57.7% |
| 2023 | -1.06x | $-125.18 Million | $118.25 Million | ▲ +50.7% |
| 2022 | -2.15x | $-124.82 Million | $58.10 Million | ▼ -19.4% |
| 2021 | -1.80x | $-71.93 Million | $39.98 Million | ▼ -19.1% |
| 2020 | -1.51x | $-38.31 Million | $25.37 Million | ▼ -36.0% |
| 2019 | -1.11x | $-29.53 Million | $26.59 Million | ▲ +18.4% |
| 2018 | -1.36x | $-19.94 Million | $14.67 Million | ▼ -294.4% |
| 2017 | -0.34x | $-20.82 Million | $60.37 Million | ▲ +38.3% |
| 2016 | -0.56x | $-23.50 Million | $42.05 Million | — |